Simcere Pharmaceutical Group
Simcere Pharmaceutical Group Ltd is a Chinese biopharmaceutical enterprise focused on discovering, developing, and commercializing prescription medicines across oncology, central nervous system, and autoimmune diseases. The company manufactures and markets branded pharmaceuticals, including Endostar for non-small cell lung cancer, Sanbexin for acute ischemic stroke, and Iremod for rheumatoid arthritis. Main revenue drivers comprise domestic commercial sales of proprietary branded oncology, CNS, and autoimmune pharmaceuticals to hospital networks and prescription pharmacies. Simcere Pharmaceutical Group serves medical oncologists, neurologists, rheumatologists, hospital networks, and patients across China and international export markets. The company holds a market-leading position in China for innovative neurology and oncology pharmaceutical therapies. Headquartered in Nanjing, Jiangsu, China, it is listed on the Hong Kong Stock Exchange.
3 of the funds FundTelligence covers report a position in Simcere Pharmaceutical Group.
- Legal name
- Simcere Pharmaceutical Group Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 3
Funds holding Simcere Pharmaceutical Group
- BNP China Equity — BNP Paribas · 0.57 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)